Insiders at REATA Pharmaceuticals (RETA) Make Significant purchases Extending the 90 day Trend

Friday, December 29, 2017 10:15 PM ET

Insiders at REATA Pharmaceuticals (RETA) Make Significant purchases Extending the 90 day Trend

The number of insider buy/sell trades at REATA Pharmaceuticals is higher than that of the 279 peer company average over the last 90-day period. The Bio Therapeutic Drugs peer group saw 319 buy/sell trades during this period for an average of 1.1 transactions per company. However, the number of shares traded per transaction by REATA Pharmaceuticals insiders is lower than its peers. Within the peer group there were 43,842,088 shares purchased and 35,496,644 shares sold with company insiders acquiring 40,316 shares on average over this time period.

In determining significant insider buying and selling, trades reported to the SEC that involve awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers have been eliminated in data sourced to compose and write this story.

Today’s Insider Activity
* CPMG Inc, 10% Owner and Director, bought 17,000 shares
* R Kent McGaughy Jr, 10% Owner and Director, bought 17,000 shares
* James W Traweek Jr, 10% Owner, bought 17,000 shares

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at info@uptickdata.com. Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.